Clinical and Molecular-Based Approach in the Evaluation of Hepatocellular Carcinoma Recurrence after Radical Liver Resection.
HCC
HCC recurrence
liver resection
loss of heterozygosity
next-generation sequencing
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Jan 2021
29 Jan 2021
Historique:
received:
31
12
2020
revised:
21
01
2021
accepted:
25
01
2021
entrez:
12
2
2021
pubmed:
13
2
2021
medline:
13
2
2021
Statut:
epublish
Résumé
Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis. 124 HCC patients, who underwent a primary hepatic resection from January 2016 to December 2019, were recruited for this study. Next-generation sequencing (NGS) analysis and allelic imbalance assessment in a case-control subgroup analysis were performed. A time-to-recurrence analysis was performed as well by means of Kaplan-Meier estimators. Cumulative number of HCC recurrences were 26 (21%) and 32 (26%), respectively, one and two years after surgery. Kaplan-Meier estimates for the probability of recurrence amounted to 37% (95% C.I.: 24-47) and to 51% (95% C.I.: 35-62), after one and two years, respectively. Multivariable analysis identified as independent predictors of HCC recurrence: hepatitis C virus (HCV) infection (HR: 1.96, 95%C.I.: 0.91-4.24, multiple alterations of cancer genes are associated with HCC progression. In particular, the evidence of a specific AI mutation presented in 20 patients seemed to have a protective effect on the risk of HCC recurrence.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatic resection remains the treatment of choice for patients with early-stage HCC with preserved liver function. Unfortunately, however, the majority of patients develop tumor recurrence. While several clinical factors were found to be associated with tumor recurrence, HCC pathogenesis is a complex process of accumulation of somatic genomic alterations, which leads to a huge molecular heterogeneity that has not been completely understood. The aim of this study is to complement potentially predictive clinical and pathological factors with next-generation sequencing genomic profiling and loss of heterozygosity analysis.
METHODS
METHODS
124 HCC patients, who underwent a primary hepatic resection from January 2016 to December 2019, were recruited for this study. Next-generation sequencing (NGS) analysis and allelic imbalance assessment in a case-control subgroup analysis were performed. A time-to-recurrence analysis was performed as well by means of Kaplan-Meier estimators.
RESULTS
RESULTS
Cumulative number of HCC recurrences were 26 (21%) and 32 (26%), respectively, one and two years after surgery. Kaplan-Meier estimates for the probability of recurrence amounted to 37% (95% C.I.: 24-47) and to 51% (95% C.I.: 35-62), after one and two years, respectively. Multivariable analysis identified as independent predictors of HCC recurrence: hepatitis C virus (HCV) infection (HR: 1.96, 95%C.I.: 0.91-4.24,
CONCLUSIONS
CONCLUSIONS
multiple alterations of cancer genes are associated with HCC progression. In particular, the evidence of a specific AI mutation presented in 20 patients seemed to have a protective effect on the risk of HCC recurrence.
Identifiants
pubmed: 33572904
pii: cancers13030518
doi: 10.3390/cancers13030518
pmc: PMC7866287
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Updates Surg. 2020 Mar;72(1):109-117
pubmed: 31625024
Pathology. 2018 Jun;50(4):389-401
pubmed: 29752127
Ann Transplant. 2019 Apr 24;24:223-233
pubmed: 31015392
J Hepatol. 2016 Nov;65(5):1031-1042
pubmed: 27262756
World J Gastroenterol. 2012 Apr 7;18(13):1438-47
pubmed: 22509075
Cardiovasc Intervent Radiol. 2010 Dec;33(6):1111-9
pubmed: 20401610
Nat Genet. 2002 Aug;31(4):339-46
pubmed: 12149612
J Surg Oncol. 2011 Feb;103(2):140-7
pubmed: 21259247
Nat Genet. 2015 May;47(5):505-511
pubmed: 25822088
JAMA Surg. 2019 Mar 1;154(3):209-217
pubmed: 30422241
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749
J Hepatol. 2020 May;72(5):896-908
pubmed: 31887370
J Laparoendosc Adv Surg Tech A. 2020 Oct;30(10):1072-1075
pubmed: 32721269
Cancer Cell. 2018 Nov 12;34(5):852-862.e4
pubmed: 30393068
Cell. 2017 Jun 15;169(7):1327-1341.e23
pubmed: 28622513
Nat Genet. 2014 Dec;46(12):1267-73
pubmed: 25362482
Lancet Oncol. 2020 Jul;21(7):947-956
pubmed: 32615109
Gastroenterology. 2015 Oct;149(5):1226-1239.e4
pubmed: 26099527
Oncotarget. 2017 Sep 1;8(44):75822-75833
pubmed: 29100271
World J Gastroenterol. 2016 Nov 7;22(41):9069-9095
pubmed: 27895396
J Laparoendosc Adv Surg Tech A. 2020 Oct;30(10):1046-1047
pubmed: 32808878
J Hepatol. 2018 Jul;69(1):182-236
pubmed: 29628281
Am Surg. 2005 Mar;71(3):235-40
pubmed: 15869140
J Laparoendosc Adv Surg Tech A. 2020 Oct;30(10):1066-1071
pubmed: 32716674
Liver Transpl. 2003 Jul;9(7):664-71
pubmed: 12827550
J Hepatol. 2018 Dec;69(6):1284-1293
pubmed: 30236834
Gastroenterology. 2019 Dec;157(6):1630-1645.e6
pubmed: 31560893